Bravelle

Bravelle

A lyophilised formulation of follicle-stimulating hormone purified from the urine of postmenopausal women, which is used to induce ovulation and as part of the regimen for assisted reproductive technologies—e.g., in vitro fertilisation.

Contraindications Bravelle
• High FSH level indicating primary ovarian failure;
• Uncontrolled thyroid and adrenal dysfunction;
• An organic intracranial lesion—especially pituitary tumours;
• Any cause of infertility other than anovulation;
• Abnormal bleeding of undetermined origin;
• Ovarian cysts or enlargement not due to polycystic ovary syndrome;
• Prior hypersensitivity to urofollitropins, purified;
• Pregnancy.
Mentioned in ?
References in periodicals archive ?
The FDA permitted for MENOPUR and BRAVELLE mixed and administered in a single injection and it sanctioning was also based on pharmacodynamics study, that evaluated safety and stability of the treatment.
FSH (Gonal-F, Bravelle, Follistim), like HMG, directly stimulates the follicles and eggs to grow.
The label update comes as an output of the COMBINE trial which revealed that MENOPUR as well as BRAVELLE can be safely mixed and administered in a single injection.
The Company markets BRAVELLE, MENOPUR, REPRONEX[R] (menotropins for injection, USP), NOVAREL and ENDOMETRIN in the U.